IMUNON INC

IMNNNASDAQ

🏆 #3737 by market capEarnings Aug 11 · PreUS Equity

$1.61▼ $0.02 (−1.23%)

Live

1h—

24h▼ 1.2%

7d—

14d—

30d—

1y—

🏦Market Cap

$7M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

34.1%

Moderate

💵FCF Margin

1159.6%

Strong

⚖️P/S Ratio

13.1x

Elevated

Otter Score

Weak

No chart data available for IMNN.

Trading Snapshot

Day Range: $1.59 – $1.64
52-Week Range: $1.47 – $7.28
Volume: $2.49B
Avg Volume: $2.72B
Shares Outstanding: 4.2M
Next Earnings: Oct 1, 2026

Fundamentals Snapshot

Annual Revenue: $523,662
Last Q Revenue: $130,785
P/E Ratio: —
P/S Ratio: 13.1x
EPS (TTM): $-5.74
Dividend Yield: —

Why Investors Own IMNN

✓High-growth profile — revenue up +25.4% YoY with expanding US Equity exposure.
✓Healthy economics — 39% gross margin and 28% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$523,662▲ +21.4% YoY

Gross Margin (TTM)

39.3%▲ +1.7% YoY

Operating Income (TTM)

$170,714▲ +21.4% YoY

Free Cash Flow (TTM)

$145,578▲ +21.4% YoY

About IMUNON INC

Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.

🦦